BR0106682A - Molécula de anticorpo, variante de molécula de anticorpo, anticorpo, composto, sequência de dna, vetor de clonagem ou de expressão, vetor de expressão de e. coli, célula hospedeira, processo para a produção da molécula de anticorpo, composição terapêutica ou diagnóstica, uso da molécula de anticorpo, vetorpdnabeng-g1, vetorptto(cdp870), e, polipeptìdeo - Google Patents
Molécula de anticorpo, variante de molécula de anticorpo, anticorpo, composto, sequência de dna, vetor de clonagem ou de expressão, vetor de expressão de e. coli, célula hospedeira, processo para a produção da molécula de anticorpo, composição terapêutica ou diagnóstica, uso da molécula de anticorpo, vetorpdnabeng-g1, vetorptto(cdp870), e, polipeptìdeoInfo
- Publication number
- BR0106682A BR0106682A BR0106682-0A BR0106682A BR0106682A BR 0106682 A BR0106682 A BR 0106682A BR 0106682 A BR0106682 A BR 0106682A BR 0106682 A BR0106682 A BR 0106682A
- Authority
- BR
- Brazil
- Prior art keywords
- antibody molecule
- antibody
- expression vector
- cdp870
- cloning
- Prior art date
Links
- 108091028043 Nucleic acid sequence Proteins 0.000 title abstract 3
- 239000013604 expression vector Substances 0.000 title abstract 3
- 238000010367 cloning Methods 0.000 title abstract 2
- 239000013599 cloning vector Substances 0.000 title abstract 2
- 150000001875 compounds Chemical class 0.000 title abstract 2
- 229920001184 polypeptide Polymers 0.000 title abstract 2
- 102000004196 processed proteins & peptides Human genes 0.000 title abstract 2
- 108090000765 processed proteins & peptides Proteins 0.000 title abstract 2
- 238000000034 method Methods 0.000 title 1
- 230000001225 therapeutic effect Effects 0.000 title 1
- 239000013598 vector Substances 0.000 abstract 2
- 241000699670 Mus sp. Species 0.000 abstract 1
- 229960003115 certolizumab pegol Drugs 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/241—Tumor Necrosis Factors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6845—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a cytokine, e.g. growth factors, VEGF, TNF, a lymphokine or an interferon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6875—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody being a hybrid immunoglobulin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Microbiology (AREA)
- Endocrinology (AREA)
- Mycology (AREA)
- Transplantation (AREA)
- Pain & Pain Management (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Compression Of Band Width Or Redundancy In Fax (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0013810.7A GB0013810D0 (en) | 2000-06-06 | 2000-06-06 | Biological products |
| PCT/GB2001/002477 WO2001094585A1 (en) | 2000-06-06 | 2001-06-05 | Antibody molecules having specificity for human tumor necrosis factor alpha, and use thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR0106682A true BR0106682A (pt) | 2002-05-14 |
Family
ID=9893121
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI0106682A BRPI0106682B8 (pt) | 2000-06-06 | 2001-06-05 | molécula de anticorpo, composto, seqüência de dna, vetor de clonagem ou de expressão, célula hospedeira, processo para a produção da molécula de anticorpo, composição terapêutica ou diagnóstica, uso da molécula de anticorpo e uso do composto |
| BR0106682-0A BR0106682A (pt) | 2000-06-06 | 2001-06-05 | Molécula de anticorpo, variante de molécula de anticorpo, anticorpo, composto, sequência de dna, vetor de clonagem ou de expressão, vetor de expressão de e. coli, célula hospedeira, processo para a produção da molécula de anticorpo, composição terapêutica ou diagnóstica, uso da molécula de anticorpo, vetorpdnabeng-g1, vetorptto(cdp870), e, polipeptìdeo |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI0106682A BRPI0106682B8 (pt) | 2000-06-06 | 2001-06-05 | molécula de anticorpo, composto, seqüência de dna, vetor de clonagem ou de expressão, célula hospedeira, processo para a produção da molécula de anticorpo, composição terapêutica ou diagnóstica, uso da molécula de anticorpo e uso do composto |
Country Status (43)
Families Citing this family (105)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0013810D0 (en) * | 2000-06-06 | 2000-07-26 | Celltech Chiroscience Ltd | Biological products |
| CA2385745C (en) | 2001-06-08 | 2015-02-17 | Abbott Laboratories (Bermuda) Ltd. | Methods of administering anti-tnf.alpha. antibodies |
| US20060073141A1 (en) * | 2001-06-28 | 2006-04-06 | Domantis Limited | Compositions and methods for treating inflammatory disorders |
| GB0129105D0 (en) | 2001-12-05 | 2002-01-23 | Celltech R&D Ltd | Expression control using variable intergenic sequences |
| PT1495056E (pt) * | 2002-03-20 | 2011-03-29 | Ucb Pharma Sa | Métodos de análise |
| US20040009172A1 (en) * | 2002-04-26 | 2004-01-15 | Steven Fischkoff | Use of anti-TNFalpha antibodies and another drug |
| GB0210121D0 (en) * | 2002-05-02 | 2002-06-12 | Celltech R&D Ltd | Biological products |
| PL222725B1 (pl) | 2002-05-02 | 2016-08-31 | Wyeth Corp | Sposób wytwarzania kompozycji i kompozycja zawierająca monomeryczne koniugaty pochodna kalicheamycyny/przeciwciało anty-CD22 o zmniejszonej zawartości frakcji niskoskoniugowanej |
| ES2370710T3 (es) | 2002-05-28 | 2011-12-22 | Ucb Pharma, S.A. | ISÓMERO POSICIONAL DE PEG DE UN ANTICUERPO ANTI-TNFalfa (CDP870). |
| US9321832B2 (en) | 2002-06-28 | 2016-04-26 | Domantis Limited | Ligand |
| US8715664B2 (en) | 2005-05-16 | 2014-05-06 | Abbvie Biotechnology Ltd. | Use of human TNFα antibodies for treatment of erosive polyarthritis |
| EP2336182A1 (en) * | 2002-07-19 | 2011-06-22 | Abbott Biotechnology Ltd | Treatment of TNF alpha related disorders |
| AU2003265361A1 (en) * | 2002-08-28 | 2004-03-19 | Pharmacia Corporation | Stable ph optimized formulation of a modified antibody |
| WO2004019860A2 (en) * | 2002-08-28 | 2004-03-11 | Pharmacia Corporation | Formulations of modified antibodies and methods of making the same |
| US20040105858A1 (en) * | 2002-08-29 | 2004-06-03 | Kim Joanne Young Hee Kwak | Diagnosis and treatment of infertility |
| MY150740A (en) | 2002-10-24 | 2014-02-28 | Abbvie Biotechnology Ltd | Low dose methods for treating disorders in which tnf? activity is detrimental |
| AU2003277828B2 (en) | 2002-10-29 | 2009-06-04 | Anaphore, Inc. | Trimeric binding proteins for trimeric cytokines |
| US7101978B2 (en) | 2003-01-08 | 2006-09-05 | Applied Molecular Evolution | TNF-α binding molecules |
| AU2004205684A1 (en) * | 2003-01-23 | 2004-08-05 | Genentech, Inc. | Methods for producing humanized antibodies and improving yield of antibodies or antigen binding fragments in cell culture |
| GB0303337D0 (en) * | 2003-02-13 | 2003-03-19 | Celltech R&D Ltd | Biological products |
| MXPA05008785A (es) * | 2003-02-19 | 2005-10-18 | Pharmacia Corp | Esteres de polietilen glicol activados. |
| WO2004098578A2 (en) * | 2003-05-12 | 2004-11-18 | Altana Pharma Ag | Composition comprising a pde4 inhibitor and a tnf-alfa antagonist selected from infliximab, adalimumab, cdp870 and cdp517 |
| EP2221317A3 (en) * | 2003-06-30 | 2011-07-27 | Domantis Limited | PEGylated single domain antibodies (dAb) |
| WO2005014649A2 (en) * | 2003-08-08 | 2005-02-17 | Pharmacia Corporation | Method for the preparation of molecules having antibody activity |
| JP5544063B2 (ja) * | 2003-08-13 | 2014-07-09 | サンド・アクチエンゲゼルシヤフト | 組換えポリペプチドの生産のための発現ベクター、形質転換宿主細胞及び発酵方法 |
| SI1656455T1 (sl) * | 2003-08-13 | 2012-12-31 | Sandoz Ag | Postopek za čiščenje rekombinantnih polipeptidov |
| GB0319601D0 (en) * | 2003-08-20 | 2003-09-24 | Sandoz Ag | Production process |
| KR100570422B1 (ko) * | 2003-10-16 | 2006-04-11 | 한미약품 주식회사 | 대장균 분비서열을 이용하여 항체 단편을 분비·생산하는 발현벡터 및 이를 이용하여 항체 단편을 대량 생산하는 방법 |
| CN100393748C (zh) * | 2003-11-06 | 2008-06-11 | 上海中信国健药业有限公司 | 全人源肿瘤坏死因子抗体，其制备方法以及药物组合物 |
| KR100772800B1 (ko) * | 2003-11-17 | 2007-11-01 | 주식회사유한양행 | 인간 종양괴사인자 α를 인식하는 단일클론항체의가변영역 및 이를 코딩하는 유전자 |
| US7435799B2 (en) | 2004-01-08 | 2008-10-14 | Applied Molecular Evolution | TNF-α binding molecules |
| CN100427504C (zh) * | 2004-06-02 | 2008-10-22 | 北京天广实生物技术有限公司 | TNFα高亲和力嵌合抗体及其用途 |
| JP2008504356A (ja) * | 2004-06-30 | 2008-02-14 | ドマンティス リミテッド | 炎症性疾患を治療するための組成物及び方法 |
| GB0425972D0 (en) * | 2004-11-25 | 2004-12-29 | Celltech R&D Ltd | Biological products |
| US8022040B2 (en) * | 2004-11-29 | 2011-09-20 | The Regents Of The University Of California | Hydroxyapatite-binding peptides for bone growth and inhibition |
| ES2359567T3 (es) * | 2004-12-29 | 2011-05-24 | Yuhan Corporation | Anticuerpo humanizado específico para el factor de necrosis tumoral-alfa. |
| CA2609234C (en) * | 2005-06-01 | 2014-04-22 | Micromet Ag | Anti-il2 antibodies |
| BRPI0611765B1 (pt) | 2005-06-07 | 2022-09-27 | Esbatech Ag | Anticorpo ou fragmento de anticorpo estável e solúvel que se liga especificamente ao tnf-alfa seus usos e composição diagnóstica ou terapêutica |
| GB0520169D0 (en) | 2005-10-04 | 2005-11-09 | Celltech R&D Ltd | Biological products |
| US9101670B2 (en) | 2006-04-07 | 2015-08-11 | Nektar Therapeutics | Conjugates of an anti-TNF-α antibody |
| EP2666472A3 (en) * | 2006-04-10 | 2014-04-02 | Abbott Biotechnology Ltd | Uses and compositions for treatment of psoriatic arthritis |
| US9399061B2 (en) | 2006-04-10 | 2016-07-26 | Abbvie Biotechnology Ltd | Methods for determining efficacy of TNF-α inhibitors for treatment of rheumatoid arthritis |
| US9605064B2 (en) | 2006-04-10 | 2017-03-28 | Abbvie Biotechnology Ltd | Methods and compositions for treatment of skin disorders |
| US20080131374A1 (en) * | 2006-04-19 | 2008-06-05 | Medich John R | Uses and compositions for treatment of rheumatoid arthritis |
| US20080003230A1 (en) | 2006-07-03 | 2008-01-03 | Adair Charles D | Composition for modulating the expression of cell adhesion molecules |
| EP1914242A1 (en) * | 2006-10-19 | 2008-04-23 | Sanofi-Aventis | Novel anti-CD38 antibodies for the treatment of cancer |
| US10888521B2 (en) * | 2007-03-02 | 2021-01-12 | Farnam Companies, Inc. | Sustained release compositions using wax-like materials |
| US20080305115A1 (en) * | 2007-06-07 | 2008-12-11 | Tice Thomas R | Reduced-mass, long-acting dosage forms |
| WO2008154543A2 (en) | 2007-06-11 | 2008-12-18 | Abbott Biotechnology Ltd. | Methods for treating juvenile idiopathic arthritis |
| WO2009026274A1 (en) * | 2007-08-22 | 2009-02-26 | Medarex, Inc. | Site-specific attachment of drugs or other agents to engineered antibodies with c-terminal extensions |
| BRPI0907485A2 (pt) * | 2008-02-05 | 2015-08-04 | Delenex Therapeutics Ag | Polipeptídeos de ligação a antígeno contra degeneração de cartilagem |
| BRPI0912570B8 (pt) * | 2008-05-07 | 2021-05-25 | Argos Therapeutics Inc | anticorpo anti-ifn-alfa humanizado, ou um fragmento de ligação ao antígeno do mesmo, composição terapêutica e seus usos |
| SI3628686T1 (sl) | 2008-06-25 | 2022-01-31 | Novartis Ag | Humaniziranje zajčjih protiteles z uporabo univerzalnega ogrodja protitelesa |
| JP5956752B2 (ja) | 2008-06-25 | 2016-07-27 | エスバテック − ア ノバルティス カンパニー エルエルシー | Ｖｅｇｆを阻害する安定かつ可溶性の抗体 |
| DK3628686T3 (da) | 2008-06-25 | 2021-09-06 | Novartis Ag | Humanisering af kanin-antistoffer under anvendelse af et universelt antistof-framework |
| PT2307457T (pt) * | 2008-06-25 | 2018-10-16 | Esbatech Alcon Biomed Res Unit | Anticorpos estáveis e solúveis que inibem o tnf |
| CN101684156B (zh) * | 2008-09-27 | 2011-12-28 | 苏州工业园区晨健抗体组药物开发有限公司 | 人TNFα单克隆抗体、其PEG化纳米颗粒及其应用 |
| US20110165063A1 (en) * | 2009-01-29 | 2011-07-07 | Abbott Laboratories | Il-1 binding proteins |
| CA2749966A1 (en) * | 2009-01-29 | 2010-08-05 | Abbott Laboratories | Il-1 binding proteins |
| ES2804450T3 (es) | 2009-07-10 | 2021-02-08 | Ablynx Nv | Método para la producción de dominios variables |
| DK2993231T3 (en) | 2009-09-24 | 2018-10-22 | Ucb Biopharma Sprl | Bacterial strain for recombinant protein expression with protease-low DEGP-retaining chaperone activity and deactivated Tsp and ptr genes |
| AR078751A1 (es) | 2009-10-23 | 2011-11-30 | Millennium Pharm Inc | Moleculas de anticuerpo anti-gcc (guanililo ciclasa c) y composiciones y metodos relacionados |
| GB201000587D0 (en) | 2010-01-14 | 2010-03-03 | Ucb Pharma Sa | Bacterial hoist strain |
| GB201000591D0 (en) | 2010-01-14 | 2010-03-03 | Ucb Pharma Sa | Bacterial hoist strain |
| GB201000590D0 (en) | 2010-01-14 | 2010-03-03 | Ucb Pharma Sa | Bacterial host strain |
| GB201000588D0 (en) | 2010-01-14 | 2010-03-03 | Ucb Pharma Sa | Bacterial host strain |
| GB201001791D0 (en) | 2010-02-03 | 2010-03-24 | Ucb Pharma Sa | Process for obtaining antibodies |
| US9616120B2 (en) | 2010-03-04 | 2017-04-11 | Vet Therapeutics, Inc. | Monoclonal antibodies directed to CD20 |
| CA2791866A1 (en) | 2010-03-04 | 2011-09-09 | Vet Therapeutics, Inc. | Monoclonal antibodies directed to cd52 |
| KR20130010123A (ko) | 2010-04-07 | 2013-01-25 | 아비에 인코포레이티드 | ＴＮＦ-α 결합 단백질 |
| GB201012603D0 (en) | 2010-07-27 | 2010-09-08 | Ucb Pharma Sa | Protein purification |
| GB201012599D0 (en) * | 2010-07-27 | 2010-09-08 | Ucb Pharma Sa | Process for purifying proteins |
| GB201012784D0 (en) * | 2010-07-29 | 2010-09-15 | Ucb Pharma Sa | Method |
| TWI538918B (zh) | 2010-10-20 | 2016-06-21 | 財團法人工業技術研究院 | 人源化之單株抗體、其核苷酸序列與其用途 |
| UY33679A (es) | 2010-10-22 | 2012-03-30 | Esbatech | Anticuerpos estables y solubles |
| EP2714912B1 (en) | 2011-06-01 | 2018-05-02 | Intrexon Actobiotics NV | Polycistronic expression system for bacteria |
| PL2731973T3 (pl) | 2011-07-13 | 2018-04-30 | Ucb Biopharma Sprl | Bakteryjny szczep gospodarz wykazujący ekspresję dsbc |
| EP2546267A1 (en) | 2011-07-13 | 2013-01-16 | UCB Pharma S.A. | Bacterial host strain expressing recombinant DsbC |
| EP2758512B1 (en) | 2011-09-23 | 2018-05-09 | Intrexon Actobiotics NV | Modified gram positive bacteria and uses thereof |
| US9347036B2 (en) | 2011-09-23 | 2016-05-24 | Intrexon Actobiotics Nv | Modified gram positive bacteria and uses thereof |
| WO2013087912A1 (en) | 2011-12-16 | 2013-06-20 | Synthon Biopharmaceuticals B.V. | Compounds and methods for treating inflammatory diseases |
| US9156915B2 (en) | 2012-04-26 | 2015-10-13 | Thomas Jefferson University | Anti-GCC antibody molecules |
| GB201208367D0 (en) | 2012-05-14 | 2012-06-27 | Ucb Pharma Sa | Biological product |
| RU2018130986A (ru) | 2012-08-13 | 2018-10-09 | Дженентек, Инк. | Антитела к jagged и способы их применения |
| JP2017518737A (ja) | 2014-04-21 | 2017-07-13 | ミレニアム ファーマシューティカルズ， インコーポレイテッドＭｉｌｌｅｎｎｉｕｍ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． | ＳＹＫ標的治療薬のための抗ｐＳＹＫ抗体分子及びその使用 |
| WO2016065052A1 (en) | 2014-10-22 | 2016-04-28 | Extend Biosciences, Inc. | Insulin vitamin d conjugates |
| US9585934B2 (en) | 2014-10-22 | 2017-03-07 | Extend Biosciences, Inc. | Therapeutic vitamin D conjugates |
| CN107108691B (zh) | 2014-12-22 | 2021-06-29 | Ucb生物制药私人有限公司 | 蛋白质制造方法 |
| US11091559B2 (en) | 2015-08-27 | 2021-08-17 | Celldex Therapeutics, Inc. | Anti-ALK antibodies and methods for use thereof |
| GB201522394D0 (en) | 2015-12-18 | 2016-02-03 | Ucb Biopharma Sprl | Antibodies |
| AU2017208153B2 (en) | 2016-01-14 | 2021-01-28 | Intrexon Actobiotics N.V. | Compositions and methods for the treatment of type 1 diabetes |
| RU2680011C2 (ru) * | 2016-04-29 | 2019-02-14 | Закрытое Акционерное Общество "Биокад" | Триспецифические антитела против il-17a, il-17f и другой провоспалительной молекулы |
| MY194619A (en) | 2016-06-02 | 2022-12-07 | Abbvie Inc | Glucocorticoid receptor agonist and immunoconjugates thereof |
| BR112020010694A2 (pt) | 2017-12-01 | 2020-11-10 | Abbvie Inc. | agonista de receptor de glicocorticoides e imunoconjugados do mesmo |
| WO2020157305A1 (en) | 2019-01-31 | 2020-08-06 | Numab Therapeutics AG | Multispecific antibodies having specificity for tnfa and il-17a, antibodies targeting il-17a, and methods of use thereof |
| KR102323342B1 (ko) * | 2019-04-26 | 2021-11-08 | 주식회사 와이바이오로직스 | IL-17A 및 TNF-α에 특이적으로 결합하는 이중표적 항체 |
| CN111909268B (zh) * | 2019-05-07 | 2022-04-19 | 北京天成新脉生物技术有限公司 | 低免疫原性低ADCC/CDC功能抗TNF-α人源化单克隆抗体TCX060及其应用 |
| TW202237638A (zh) | 2020-12-09 | 2022-10-01 | 日商武田藥品工業股份有限公司 | 烏苷酸環化酶ｃ（ｇｃｃ）抗原結合劑之組成物及其使用方法 |
| TW202237639A (zh) | 2020-12-09 | 2022-10-01 | 日商武田藥品工業股份有限公司 | 鳥苷酸環化酶ｃ（ｇｃｃ）抗原結合劑之組成物及其使用方法 |
| US20240226295A9 (en) | 2021-02-15 | 2024-07-11 | Takeda Pharmaceutical Company Limited | Cell therapy compositions and methods for modulating tgf-b signaling |
| EP4393937A1 (en) | 2021-08-26 | 2024-07-03 | Duality Biologics (Suzhou) Co., Ltd. | Steroid compound and conjugate thereof |
| KR20240099199A (ko) | 2021-09-24 | 2024-06-28 | 엑스브레인 바이오파마 에이비 | 재조합 단백질을 발현시키기 위한 dna 구조체 및 숙주 세포 |
| SE545694C2 (en) * | 2021-09-24 | 2023-12-05 | Xbrane Biopharma Ab | Dna construct comprising nucleotide sequences encoding amino acid sequences of certolizumab and pelb signal peptides |
| SE545714C2 (en) * | 2021-09-24 | 2023-12-19 | Xbrane Biopharma Ab | Dna contructs for producing a pelb signal peptide |
| WO2023154799A1 (en) | 2022-02-14 | 2023-08-17 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Combination immunotherapy for treating cancer |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8422238D0 (en) | 1984-09-03 | 1984-10-10 | Neuberger M S | Chimeric proteins |
| DK336987D0 (da) | 1987-07-01 | 1987-07-01 | Novo Industri As | Immobiliseringsmetode |
| GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
| GB8719042D0 (en) | 1987-08-12 | 1987-09-16 | Parker D | Conjugate compounds |
| US5030570A (en) | 1988-06-30 | 1991-07-09 | The Eunice Kennedy Shriver Center For Mental Retardation | DNA encoding and method of expressing human monoamine oxidase type A |
| IL162181A (en) | 1988-12-28 | 2006-04-10 | Pdl Biopharma Inc | A method of producing humanized immunoglubulin, and polynucleotides encoding the same |
| PT92900A (pt) * | 1989-01-24 | 1990-07-31 | Sistema de vectores de expressao para a producao de anticorpos monoclonais quimericos | |
| GB8907617D0 (en) | 1989-04-05 | 1989-05-17 | Celltech Ltd | Drug delivery system |
| GB8928874D0 (en) | 1989-12-21 | 1990-02-28 | Celltech Ltd | Humanised antibodies |
| GB9109645D0 (en) * | 1991-05-03 | 1991-06-26 | Celltech Ltd | Recombinant antibodies |
| US5919452A (en) | 1991-03-18 | 1999-07-06 | New York University | Methods of treating TNFα-mediated disease using chimeric anti-TNF antibodies |
| GB9112536D0 (en) | 1991-06-11 | 1991-07-31 | Celltech Ltd | Chemical compounds |
| GB9120467D0 (en) | 1991-09-26 | 1991-11-06 | Celltech Ltd | Anti-hmfg antibodies and process for their production |
| NO309690B1 (no) | 1995-01-23 | 2001-03-12 | Western Atlas Int Inc | Detonasjonsanordning av type eksploderende brotråd for bruk med et perforeringsverktöy i en brönn |
| CA2218522A1 (en) | 1995-04-20 | 1996-10-24 | The Kennedy Institute Of Rheumatology | Multiple administrations of anti-tnf antibody |
| SI9720020B (en) | 1996-02-09 | 2001-12-31 | Basf Ag | Human antibodies that bind human TNF alpha |
| US5980898A (en) | 1996-11-14 | 1999-11-09 | The United States Of America As Represented By The U.S. Army Medical Research & Material Command | Adjuvant for transcutaneous immunization |
| GB9625640D0 (en) | 1996-12-10 | 1997-01-29 | Celltech Therapeutics Ltd | Biological products |
| AU9262598A (en) * | 1997-08-18 | 1999-03-08 | Innogenetics N.V. | Interferon-gamma-binding molecules for treating septic shock, cachexia, immune diseases and skin disorders |
| GB9720054D0 (en) * | 1997-09-19 | 1997-11-19 | Celltech Therapeutics Ltd | Biological products |
| ATE399809T1 (de) | 1998-03-12 | 2008-07-15 | Nektar Therapeutics Al Corp | Verfahren zur herstellung von polymerkonjugaten |
| GB9812545D0 (en) * | 1998-06-10 | 1998-08-05 | Celltech Therapeutics Ltd | Biological products |
| GB0013810D0 (en) * | 2000-06-06 | 2000-07-26 | Celltech Chiroscience Ltd | Biological products |
-
2000
- 2000-06-06 GB GBGB0013810.7A patent/GB0013810D0/en not_active Ceased
-
2001
- 2001-06-05 EP EP10010795.2A patent/EP2308975B1/en not_active Expired - Lifetime
- 2001-06-05 AU AU60511/01A patent/AU783756B2/en active Active
- 2001-06-05 PL PL353960A patent/PL212738B1/pl unknown
- 2001-06-05 SI SI200131056A patent/SI2308975T1/sl unknown
- 2001-06-05 DK DK10010795.2T patent/DK2308975T3/da active
- 2001-06-05 PT PT100107952T patent/PT2308975T/pt unknown
- 2001-06-05 DK DK09176251.8T patent/DK2230308T3/da active
- 2001-06-05 RU RU2002105922/13A patent/RU2303604C2/ru active Protection Beyond IP Right Term
- 2001-06-05 MY MYPI20012634A patent/MY136603A/en unknown
- 2001-06-05 BR BRPI0106682A patent/BRPI0106682B8/pt not_active IP Right Cessation
- 2001-06-05 BR BR0106682-0A patent/BR0106682A/pt not_active IP Right Cessation
- 2001-06-05 DK DK01934209.6T patent/DK1287140T3/da active
- 2001-06-05 NZ NZ516596A patent/NZ516596A/en not_active IP Right Cessation
- 2001-06-05 MX MXPA01013440A patent/MXPA01013440A/es active IP Right Grant
- 2001-06-05 WO PCT/GB2001/002477 patent/WO2001094585A1/en active Application Filing
- 2001-06-05 TR TR2019/00227T patent/TR201900227T4/tr unknown
- 2001-06-05 OA OA1200200368A patent/OA12282A/en unknown
- 2001-06-05 LT LTEP10010795.2T patent/LT2308975T/lt unknown
- 2001-06-05 CA CA2707766A patent/CA2707766C/en not_active Expired - Lifetime
- 2001-06-05 SI SI200131020T patent/SI2230308T1/sl unknown
- 2001-06-05 CN CNB018016294A patent/CN1289671C/zh not_active Expired - Lifetime
- 2001-06-05 EP EP16154916.7A patent/EP3059314B1/en not_active Expired - Lifetime
- 2001-06-05 HU HU0202346A patent/HU230561B1/hu active Protection Beyond IP Right Term
- 2001-06-05 PT PT01934209T patent/PT1287140E/pt unknown
- 2001-06-05 SI SI200130960T patent/SI1287140T1/sl unknown
- 2001-06-05 PL PL399351A patent/PL218516B1/pl unknown
- 2001-06-05 ES ES10010795.2T patent/ES2600080T3/es not_active Expired - Lifetime
- 2001-06-05 JP JP2002502126A patent/JP4064812B2/ja not_active Expired - Lifetime
- 2001-06-05 ES ES01934209T patent/ES2337763T3/es not_active Expired - Lifetime
- 2001-06-05 ES ES09176251T patent/ES2403217T3/es not_active Expired - Lifetime
- 2001-06-05 AT AT01934209T patent/ATE451460T1/de active
- 2001-06-05 PT PT16154916T patent/PT3059314T/pt unknown
- 2001-06-05 HU HU1600016A patent/HU230553B1/hu unknown
- 2001-06-05 SK SK315-2002A patent/SK288343B6/sk not_active IP Right Cessation
- 2001-06-05 AP APAP/P/2002/002690A patent/AP2092A/en active
- 2001-06-05 EP EP01934209A patent/EP1287140B1/en not_active Expired - Lifetime
- 2001-06-05 DE DE122010000027C patent/DE122010000027I1/de active Pending
- 2001-06-05 ES ES16154916T patent/ES2707714T3/es not_active Expired - Lifetime
- 2001-06-05 DE DE10192353T patent/DE10192353T1/de not_active Withdrawn
- 2001-06-05 KR KR1020027001131A patent/KR20020047097A/ko active Search and Examination
- 2001-06-05 GB GB0128386A patent/GB2366800B/en not_active Expired - Lifetime
- 2001-06-05 IL IL14799201A patent/IL147992A0/xx unknown
- 2001-06-05 ES ES200250012A patent/ES2230975B2/es not_active Expired - Lifetime
- 2001-06-05 EP EP09176251A patent/EP2230308B1/en not_active Expired - Lifetime
- 2001-06-05 CZ CZ20020837A patent/CZ300737B6/cs unknown
- 2001-06-05 PT PT91762518T patent/PT2230308E/pt unknown
- 2001-06-05 DE DE60140738T patent/DE60140738D1/de not_active Expired - Lifetime
- 2001-06-05 CA CA2380298A patent/CA2380298C/en not_active Expired - Lifetime
- 2001-06-05 HU HUP1600483A patent/HU230669B1/hu unknown
- 2001-06-05 DK DK16154916.7T patent/DK3059314T3/en active
- 2001-06-06 PE PE2001000529A patent/PE20020292A1/es active IP Right Grant
- 2001-06-06 TW TW096150671A patent/TWI353358B/zh not_active IP Right Cessation
- 2001-06-06 AR ARP010102689A patent/AR033978A1/es active IP Right Grant
- 2001-06-06 TW TW090113707A patent/TWI316088B/zh active
- 2001-06-06 US US09/875,221 patent/US7012135B2/en not_active Expired - Lifetime
- 2001-09-10 US US09/949,559 patent/US7186820B2/en not_active Expired - Lifetime
-
2002
- 2002-01-03 IS IS6217A patent/IS2808B/is unknown
- 2002-01-04 ZA ZA200200097A patent/ZA200200097B/xx unknown
- 2002-01-04 BG BG106278A patent/BG66072B1/bg unknown
- 2002-02-04 IL IL147992A patent/IL147992A/en active IP Right Grant
- 2002-02-04 NO NO20020554A patent/NO334808B1/no not_active IP Right Cessation
- 2002-02-06 EC EC2002004210A patent/ECSP024210A/es unknown
-
2003
- 2003-05-22 HK HK03103635.2A patent/HK1051385A1/xx not_active IP Right Cessation
-
2006
- 2006-03-13 US US11/374,231 patent/US7402662B2/en not_active Expired - Lifetime
- 2006-10-19 JP JP2006285205A patent/JP4476989B2/ja not_active Expired - Lifetime
-
2008
- 2008-06-18 US US12/141,667 patent/US7977464B2/en not_active Expired - Fee Related
- 2008-11-03 IL IL195085A patent/IL195085A0/en unknown
-
2009
- 2009-01-09 JP JP2009003953A patent/JP5185143B2/ja not_active Expired - Lifetime
-
2010
- 2010-03-09 CY CY20101100219T patent/CY1109889T1/el unknown
- 2010-03-15 FR FR10C0015C patent/FR10C0015I2/fr active Active
- 2010-03-29 LU LU91674C patent/LU91674I2/fr unknown
- 2010-04-13 BE BE2010C019C patent/BE2010C019I2/fr unknown
- 2010-05-13 CY CY2010011C patent/CY2010011I2/el unknown
-
2011
- 2011-03-22 HK HK11102887.9A patent/HK1148776A1/xx not_active IP Right Cessation
- 2011-11-18 IS IS8986A patent/IS3016B/is unknown
-
2013
- 2013-04-23 CY CY20131100333T patent/CY1114143T1/el unknown
- 2013-10-01 NO NO20131316A patent/NO339282B1/no not_active IP Right Cessation
-
2014
- 2014-10-23 NO NO2014026C patent/NO2014026I2/no unknown
-
2016
- 2016-04-26 NO NO20160694A patent/NO341218B1/no not_active IP Right Cessation
- 2016-11-10 CY CY20161101159T patent/CY1118220T1/el unknown
-
2017
- 2017-04-06 HU HUS1700013C patent/HUS1700013I1/hu unknown
-
2019
- 2019-01-24 CY CY20191100095T patent/CY1121173T1/el unknown
- 2019-04-19 CY CY2019018C patent/CY2019018I2/el unknown
- 2019-04-24 NL NL300982C patent/NL300982I9/nl unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR0106682A (pt) | Molécula de anticorpo, variante de molécula de anticorpo, anticorpo, composto, sequência de dna, vetor de clonagem ou de expressão, vetor de expressão de e. coli, célula hospedeira, processo para a produção da molécula de anticorpo, composição terapêutica ou diagnóstica, uso da molécula de anticorpo, vetorpdnabeng-g1, vetorptto(cdp870), e, polipeptìdeo | |
| BR0212756A (pt) | Molécula de anticorpo tendo especificidade para kdr humano, variante da molécula de anticorpo, composto, sequência de dna, vetor, célula hospedeira, processo para a produção da molécula de anticorpo, composição terapêutica ou diagnóstica, e, uso da molécula de anticorpo | |
| BR0007414A (pt) | Expressão e exportação de proteìnas antiobesidade como proteìnas de fusão fc | |
| O'Donnell et al. | Total reconstitution of DNA polymerase III holoenzyme reveals dual accessory protein clamps. | |
| NL300920I2 (nl) | inotuzumab ozogamicine | |
| KR920700228A (ko) | 단일영역 리간드와 이를 포함하는 수용체 및 이들의 제조방법과 이용(법) | |
| BR9814404A (pt) | " clonagem de expressão em fungos filamentosos " | |
| CL2009000575A1 (es) | Anticuerpos aislados anti-interleuquina 12 (anti il-12) de mamiferos, secuencia de nucleotidos, vector, celula y metodo de produccion, composicion y dispositivo medico que contienen, util en el diagnostico y tratamiento de condicones relacionadas con il-12. | |
| DE69936104D1 (de) | Nukleinsäuresequenzen des adeno-assoziierten virus des serotyps i, und vektoren und wirtszellen, die diese enthalten | |
| BR0011849A (pt) | Anticorpos enxertados lm609 melhorados | |
| NO20043891L (no) | Anti-A-beta-antistoffer og deres anvendelse | |
| WO1998006841A3 (en) | Two human nsp-like proteins | |
| NO981748L (no) | Nytt DNA, samt en fremgangsmÕte for fremstilling av protein ved anvendelse av dette | |
| BRPI0410655A (pt) | composição farmacêutica, método de tratar ou prevenir uma infecção pelo vìrus da raiva em um indivìduo em necessidade deste tratamento, vetor de expressão de rhabdovìrus recombinante, célula hospedeira de mamìfero, método de produzir uma anticorpo recombinante humano neutralizante do vìrus da raiva em uma célula de mamìfero, e, uso de uma combinação | |
| DK0629238T3 (da) | Autotaxin:Motilitetsstimulerende protein, som er nyttigt til cancerdiagnose og terapi | |
| Imahori et al. | The circular dichroism of polynucleotides in relation to their conformations | |
| Wang et al. | A recombinant prodrug type approach for triggered delivery of streptokinase | |
| BRPI0309730B8 (pt) | molécula de anticorpo possuindo especificidade para cd22 humana, sequência de dna, vetor de expressão ou clonagem, célula hospedeira, uso da molécula de anticorpo ou da sequência de dna, composição diagnóstica ou terapêutica, processo para a produção de uma molécula de anticorpo, processo para a preparação de uma composição diagnóstica ou terapêutica | |
| BR9909576A (pt) | Genes de receptor de transferrina de moraxella | |
| TH59463B (th) | ผลิตภัณฑ์ชีวภาพ |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B25A | Requested transfer of rights approved |
Owner name: UCB S.A. (BE) Free format text: TRANSFERIDO DE: CELLTECH RANDD LIMITED |
|
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B65X | Notification of requirement for priority examination of patent application | ||
| B65Z | Priority examination of the patent application refused (request does not comply with dec. 132/06 of 20061117) |
Free format text: NEGADO O EXAME PRIORITARIO DO PEDIDO DE PATENTE UMA VEZ QUE NAO FOI ATENDIDO O DISPOSTO NO PARAGRAFO 2O, ART.1O DA RESOLUCAO 080/13. |
|
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
| B15K | Others concerning applications: alteration of classification |
Ipc: C07K 16/24 (2006.01), A61K 47/68 (2017.01), A61K 3 |
|
| B15K | Others concerning applications: alteration of classification |
Ipc: C12N 15/13 (2006.01), C12N 15/62 (2006.01), C12N 1 |
|
| B06T | Formal requirements before examination [chapter 6.20 patent gazette] | ||
| B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
| B25A | Requested transfer of rights approved |
Owner name: UCB PHARMA S.A. (BE) |
|
| B06A | Patent application procedure suspended [chapter 6.1 patent gazette] | ||
| B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
| B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] |
Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 13/10/2020, OBSERVADAS AS CONDICOES LEGAIS. |
|
| B16C | Correction of notification of the grant [chapter 16.3 patent gazette] |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 05/06/2001 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF |
|
| B21F | Lapse acc. art. 78, item iv - on non-payment of the annual fees in time |
Free format text: REFERENTE A 22A ANUIDADE. |
|
| B21H | Decision of lapse of a patent or of a certificate of addition of invention cancelled [chapter 21.8 patent gazette] |
Free format text: ANULADA A PUBLICACAO CODIGO 21.6 NA RPI NO 2726 DE 04/04/2023 POR TER SIDO INDEVIDA. |